Last Updated：2025/11/30
In an early-phase study, ganetespib demonstrated promising antitumor activity in patients with cancers reliant on the oncogenic chaperone HSP90.
See correct answer
In an early-phase study, ganetespib demonstrated promising antitumor activity in patients with cancers reliant on the oncogenic chaperone HSP90.
音声機能が動作しない場合はこちらをご確認ください
Edit Histories（0）
